Charles River Laboratories International, Inc.· CRL
🇺🇸 US · LargeSP500NYSE
- Price
- $278.06
- Day
- -1.28%
- Mkt Cap
- $13.39B
- 52W Range
- $144.26 – $303.31
- Volume
- 1.48M
- Beta
- 1.41
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Investors looking for stocks in the Medical Services sector might want to consider either Progyny (PGNY) or Charles River Laboratories (CRL). But which of these two stocks presents investors with the better value opportunity right now?
Read full article
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has introduced rapid cell banking programs designed to significantly accelerate release timelines, enabling biopharmaceutical and advanced therapy developers to reach critical milestones faster and bring innovative treatments to patients sooner. By combining rapid cell bank and release packages with advanced characterization using Next-Generation Sequencing (NGS), Charles River delivers a comprehensiv.
Read full article
Charles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
Read full article
Charles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Read full article
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at Morgan Stanley and Baird Conferences.
Read full article
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at two upcoming investor conferences, including:Morgan Stanley 2
Read full article
Amundi trimmed its position in Charles River Laboratories International, Inc. (NYSE: CRL) by 46.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 412,402 shares of the medical research company's stock after selling 360,913 shares during the period.
Read full article
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) has successfully implemented its Endosafe® Cartridge Technology Automated Manufacturing Suite, a significant advancement in bacterial endotoxin testing cartridge production that expands in-process inspection and digital traceability, strengthens manufacturing controls and increases production capacity. Reaching full operational capacity in Q3 2026, the automated suite is a major investment in advanced.
Read full article
IHE's concentrated pharma holdings delivered 50% returns over one year, while RSPH's equal-weight healthcare approach generated 29%. Risk profiles differ sharply too.
Read full article
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Read full article
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
Read full article
Charles River Laboratories International (NYSE: CRL - Get Free Report) and IB Acquisition (NASDAQ: IBAC - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Earnings and Valuation This table compares
Read full article